DOP2014000081A - Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas - Google Patents

Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas

Info

Publication number
DOP2014000081A
DOP2014000081A DO2014000081A DO2014000081A DOP2014000081A DO P2014000081 A DOP2014000081 A DO P2014000081A DO 2014000081 A DO2014000081 A DO 2014000081A DO 2014000081 A DO2014000081 A DO 2014000081A DO P2014000081 A DOP2014000081 A DO P2014000081A
Authority
DO
Dominican Republic
Prior art keywords
procedures
compounds
immune responses
innate immune
improve innate
Prior art date
Application number
DO2014000081A
Other languages
English (en)
Spanish (es)
Inventor
Janos Botyanszki
Robert Hamatake
Hans Hofland
Jean-Philippe Therrien
Shihyun You
Anna Lindsey Banka
Eric Gregory Burroughs
John George Catalano
Wendy Huang Chern
Hamilton D Dickson
Margaret J Gartland
Jesse Daniel Keicher
Christopher Brooks Moore
John Bradford Shotwell
Matthew David Tallant
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of DOP2014000081A publication Critical patent/DOP2014000081A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DO2014000081A 2011-10-21 2014-04-21 Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas DOP2014000081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US201261692431P 2012-08-23 2012-08-23

Publications (1)

Publication Number Publication Date
DOP2014000081A true DOP2014000081A (es) 2014-07-15

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000081A DOP2014000081A (es) 2011-10-21 2014-04-21 Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas

Country Status (23)

Country Link
US (1) US20140249143A1 (enExample)
EP (1) EP2768506A4 (enExample)
JP (1) JP2014532626A (enExample)
KR (1) KR20140094559A (enExample)
CN (1) CN103957910A (enExample)
AR (1) AR088793A1 (enExample)
AU (1) AU2012325971B2 (enExample)
BR (1) BR112014008727A2 (enExample)
CA (1) CA2851801A1 (enExample)
CL (1) CL2014001016A1 (enExample)
CO (1) CO6910198A2 (enExample)
CR (1) CR20140175A (enExample)
DO (1) DOP2014000081A (enExample)
EA (1) EA201490610A1 (enExample)
IL (1) IL231894A0 (enExample)
MX (1) MX2014004814A (enExample)
PE (1) PE20141359A1 (enExample)
PH (1) PH12014500865A1 (enExample)
SG (2) SG11201400988SA (enExample)
TW (2) TW201542567A (enExample)
UY (1) UY34406A (enExample)
WO (1) WO2013059559A2 (enExample)
ZA (1) ZA201402392B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
EP3200778A4 (en) * 2014-09-29 2018-05-23 The Trustees Of The University Of Pennsylvania Antivirals against molluscum contagiosum virus
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗b型肝炎ウイルス剤
CN110709400A (zh) 2017-03-28 2020-01-17 皮梅拉股份有限公司 Pol1抑制剂的新型晶体形式
EP3870581B1 (en) 2018-10-23 2023-06-14 Basf Se Tricyclic pesticidal compounds
CN114681472B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
KR20230002396A (ko) 2020-04-14 2023-01-05 바스프 에스이 트리시클릭 살충 화합물
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
CN120916763A (zh) * 2023-04-14 2025-11-07 人福医药美国公司 用于治疗疼痛和相关医学病症的单酰甘油脂肪酶(magl)抑制剂
WO2025089372A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人理化学研究所 イソインドリン誘導体
WO2025128898A1 (en) 2023-12-13 2025-06-19 Assembly Biosciences, Inc. Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59104A (en) * 1979-02-09 1984-02-29 Roussel Uclaf Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ.ホフマン−ラ ロシュ アーゲー イミダゾ縮合化合物
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US8545732B2 (en) * 2009-03-31 2013-10-01 Daikin Industries, Ltd. Electrode film for polymer actuator element, and polymer actuator element comprising the same
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Also Published As

Publication number Publication date
TW201333003A (zh) 2013-08-16
AR088793A1 (es) 2014-07-10
CA2851801A1 (en) 2013-04-25
PE20141359A1 (es) 2014-10-13
EP2768506A4 (en) 2015-08-19
BR112014008727A2 (pt) 2017-04-25
KR20140094559A (ko) 2014-07-30
SG10201505664WA (en) 2015-09-29
JP2014532626A (ja) 2014-12-08
EP2768506A2 (en) 2014-08-27
ZA201402392B (en) 2017-09-27
CO6910198A2 (es) 2014-03-31
CN103957910A (zh) 2014-07-30
IL231894A0 (en) 2014-05-28
PH12014500865A1 (en) 2014-05-26
MX2014004814A (es) 2014-05-27
AU2012325971A1 (en) 2014-04-17
CL2014001016A1 (es) 2015-01-16
US20140249143A1 (en) 2014-09-04
EA201490610A1 (ru) 2014-09-30
AU2012325971B2 (en) 2016-03-31
TW201542567A (zh) 2015-11-16
CR20140175A (es) 2014-06-03
WO2013059559A3 (en) 2013-11-14
SG11201400988SA (en) 2014-07-30
WO2013059559A2 (en) 2013-04-25
UY34406A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
DOP2014000081A (es) Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
EA201490947A1 (ru) Производные пурина для лечения вирусных инфекций
EA201491486A1 (ru) Производные пиперидинопиримидина для лечения вирусных инфекций
NI201400108A (es) Compuestos de heterociclilo
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
CO6791618A2 (es) Derivados de nucleósidos 2-sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
ECSP14013215A (es) Compuestos novedosos
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
MX2015003140A (es) Formulaciones de enzalutamida.
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
UY34262A (es) Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CR20150549A (es) Compuestos heterocíclicos y sus usos
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos